James Paul O'Neill1,2, Donal J Sexton3, Eamonn O'Leary4, Patrick O'Kelly3, Susan Murray3, Sandra Deady4, Fergus Daly3, Yvonne Williams3, Ben Dean3, Conall Fitzgerald1, Aizuri Murad5, Nazish Mansoor5, Jim O O'Neill6, Jim Egan7, Diarmaid D Houlihan8, P Aiden McCormick8, Patrick G Morris2,9, Siona Ni Raghallaigh10, Dilly Little3, Fergal J Moloney5, Peter J Conlon2,3. 1. Department of Otolaryngology, Head and Neck Surgery, Beaumont Hospital & The Royal College of Surgeons in Ireland, Dublin, Ireland. 2. Royal College of Surgeons Ireland, Dublin, Ireland. 3. Department of Transplant Urology and Nephrology, National Kidney Transplant Service, Beaumont Hospital Dublin, Dublin, Ireland. 4. National Cancer Registry Ireland, Cork, Ireland. 5. Department of Dermatology, School of Medicine, Mater Misericordiae University Hospital, University College Dublin, Dublin, Ireland. 6. National Heart Transplant Center, Mater Misericordiae University Hospital, Dublin, Ireland. 7. National Lung Transplantation Center, Mater University Hospital Dublin, Dublin, Ireland. 8. National Liver Transplant Center, St Vincent's University Hospital, Dublin, Ireland. 9. Department of Medical Oncology, Beaumont Hospital, Dublin, Ireland. 10. Department of Dermatology, Beaumont Hospital, Dublin, Ireland.
Abstract
OBJECTIVE: Solid organ transplant recipients are at increased risk of cancer compared to the general population. To date, this risk in Ireland has not been investigated. We conducted a national registry study of cancer incidence following solid organ transplantation. METHODS: National centers for solid organ transplantation supplied their respective registry databases to cross-reference with episodes of malignancy from the National Cancer Registry Ireland (NCRI) between 1994 and 2014. Standardized incidence of cancer post-transplant was compared to the general population by means of standardized incidence ratios (SIRs), and between solid organ transplant types by incidence rate ratios. RESULTS: A total of 3346 solid organ transplant recipients were included in this study. Kidney transplant recipients constituted the majority of participants (71.2%), followed by liver (16.8%), heart (6.4%), and lung (5.6%) transplants. The most common cancers within the composite of all transplant recipients included the following (SIR [95% CI]): squamous and basal cell carcinoma (20.05 [17.97, 22.31] and 7.16 [6.43, 7.96], respectively), non-Hodgkin lymphoma (6.23 [4.26, 8.59]), and renal cell carcinoma (3.36 [1.96, 5.38]). CONCLUSIONS: This study reports the incidence of cancer following solid organ transplantation in Ireland. These results have significant national policy implications for surveillance, and early diagnosis in this patient group.
OBJECTIVE: Solid organ transplant recipients are at increased risk of cancer compared to the general population. To date, this risk in Ireland has not been investigated. We conducted a national registry study of cancer incidence following solid organ transplantation. METHODS: National centers for solid organ transplantation supplied their respective registry databases to cross-reference with episodes of malignancy from the National Cancer Registry Ireland (NCRI) between 1994 and 2014. Standardized incidence of cancer post-transplant was compared to the general population by means of standardized incidence ratios (SIRs), and between solid organ transplant types by incidence rate ratios. RESULTS: A total of 3346 solid organ transplant recipients were included in this study. Kidney transplant recipients constituted the majority of participants (71.2%), followed by liver (16.8%), heart (6.4%), and lung (5.6%) transplants. The most common cancers within the composite of all transplant recipients included the following (SIR [95% CI]): squamous and basal cell carcinoma (20.05 [17.97, 22.31] and 7.16 [6.43, 7.96], respectively), non-Hodgkin lymphoma (6.23 [4.26, 8.59]), and renal cell carcinoma (3.36 [1.96, 5.38]). CONCLUSIONS: This study reports the incidence of cancer following solid organ transplantation in Ireland. These results have significant national policy implications for surveillance, and early diagnosis in this patient group.
Authors: Terhi Kristiina Friman; Salla Jäämaa-Holmberg; Fredrik Åberg; Ilkka Helanterä; Maija Halme; Markku O Pentikäinen; Arno Nordin; Karl B Lemström; Timo Jahnukainen; Riikka Räty; Birgitta Salmela Journal: Int J Cancer Date: 2022-02-03 Impact factor: 7.316